Mayo Foundation for Medical Education and Research

University of Illinois

Duke University

Ixcela, Inc.

Liewei Wang

Richard M Weinshilboum

Matthew P Goetz

Judy C Boughey

Oreste Salavaggione

Linda L Pelleymounter

Jia Yu

Wayne R Matson

Rima Kaddurah-Daouk

Eric D Wieben

Araba A Adjei

William S Brimijoin

Yang Gao

Liyi Geng

Ping Chen

Michiaki Kubo

Bo Qin

Ravishankar Krishnan Iyer

Taisei Mushiroda

Arjun Prasanna Athreya

Mark Andrew Frye

William Victor Bobo

Joanna Biernacka

Krishna R Kalari

Tanda T Dudenkov

Vera J Suman

Mark Frye

James N Ingle

Junmei Cairns

Josefa Coronel

Bruce Eckloff

Daniel Schaid

Cynthia X Ma

Balmiki Ray

Eric O Wieben

Richard Merle Weinshilboum

The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention. The predictive methods may be augmented by metabolomics data, genomics data, or other objective measures taken from a patient, allowing the use of objective physiological measures to diagnosis and treat psychological conditions heretofore diagnosed and assessed using only subjective, self-reported measures.

Analytics and machine learning framework for actionable intelligence from clinical and omics data

This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.

Methods and materials for using butyrylcholinesterases to treat cancer

This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340cancer cells such as HER2cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2breast cancer that was refractory to trastuzumab alone treatment) are provided.

Methods and materials for treating cancer

Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.

Modulating the aryl hydrocarbon receptor system to treat major depressive disorder

This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A&#x2192;G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.

Methods and materials for treating estrogen receptor positive breast cancer

This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.

Methods and materials for assessing chemotherapy responsiveness and treating cancer

Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.

HSD3B1 sequence variants

Isolated CYP19A1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as CYP19A1 allozymes. Methods for determining the aromatase status of an individual also are provided, as are methods for determining if a subject is predisposed to certain clinical conditions.

CYP19A1 polymorphisms

Growing community of inventors

Rochester, MN, United States of America

Liewei Wang